---
title: "AtaiBeckley Inc. (ATAI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATAI.US.md"
symbol: "ATAI.US"
name: "AtaiBeckley Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T16:59:48.076Z"
locales:
  - [en](https://longbridge.com/en/quote/ATAI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATAI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATAI.US.md)
---

# AtaiBeckley Inc. (ATAI.US)

## Company Overview

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.ataibeckley.com](https://www.ataibeckley.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 66 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 87.22% |  |
| Net Profit YoY | -345.27% |  |
| P/B Ratio | 7.31 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1452990908.16 |  |
| Revenue | 3488000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -378.29% | E |
| Profit Margin | -19019.44% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 87.22% | A |
| Net Profit YoY | -345.27% | E |
| Total Assets YoY | 35.29% | A |
| Net Assets YoY | 30.54% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 87.22% | A |
| Turnover | 0.02 | E |
| Gearing Ratio | 24.95% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AtaiBeckley Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "87.22%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-345.27%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.31",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1452990908.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3488000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-378.29%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-19019.44%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "87.22%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-345.27%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "35.29%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "30.54%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "87.22%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.95%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.19 | 136/189 | - | - | - |
| PB | 7.31 | 167/189 | 8.73 | 6.83 | 5.03 |
| PS (TTM) | 416.57 | 158/189 | 481.37 | 425.15 | 303.29 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 86% |
| Overweight | 2 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.08 |
| Highest Target | 25.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATAI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATAI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATAI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATAI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**